Select Drug Profiles

Skip to main content

FDA Approvals, In the News, Select Drug Profiles

FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

FDA Approvals, In the News, Select Drug Profiles

March 08, 2019 - FDA Approvals, News & Updates

FDA Approvals, In the News, Select Drug Profiles

FDA Approves Pembrolizumab for Treatment of Advanced Melanoma

FDA Approvals, In the News, Select Drug Profiles

FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma

FDA Approvals, In the News, Select Drug Profiles

February 1, 2019 - FDA Approvals, News & Updates

FDA Approvals, In the News, Select Drug Profiles

Government Shutdown Impacts FDA Drug Approvals

FDA Approvals, Select Drug Profiles

A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath

Gillian Woollett, MA, DPhil , Bruce S. Pyenson, FSA, MAAA

Select Drug Profiles, Payers' Guide

Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea

Select Drug Profiles, Payers' Guide

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

7
8
9
10
11
12
13

Page 10 of 20
Results 91 - 100 of 200